Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T15:03:10.227Z.
Calculation as of: 2026-10-06T15:03:10.227Z.
Quote observation: 2026-10-06T15:00:42.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 771dc6670e9772695969b0bf6104b917a4d7f40f340cdb77ec2424dd20cacd43
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$1.44B
Price/FCF Ratio
79.74
TTM Avg
258.29
3Y Avg
258.29
5Y Avg
172.61
Market Cap
$1.35B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.46B
Price/FCF Ratio
9.66
TTM Avg
9.98
3Y Avg
22.18
5Y Avg
99.17
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inhibrx Biosciences Inc. (INBX) | $1.40B | N/A | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.41B | N/A | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.44B | 79.74 | 258.29 | 258.29 | 172.61 |
| Omeros Corporation (OMER)vs › | $1.35B | N/A | 2.59 | 2.60 | 2.60 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A | N/A | N/A | N/A |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.35B | N/A | N/A | N/A | N/A |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.47B | N/A | 7.24 | 7.24 | 7.24 |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 9.66 | 9.98 | 22.18 | 99.17 |
| GH Research PLC (GHRS)vs › | $1.47B | N/A | N/A | N/A | N/A |
| Certara, Inc. (CERT)vs › | $1.48B | 24.03 | 16.96 | 29.77 | 40.80 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
